125 related articles for article (PubMed ID: 16723171)
1. Three-year survival in metastatic non-small cell lung cancer treated with gefitinib.
Costa DB; Schumer ST
Lung Cancer; 2006 Jul; 53(1):123-4. PubMed ID: 16723171
[No Abstract] [Full Text] [Related]
2. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
3. Long-term survival in three patients with metastatic non-small cell lung cancer treated with gefitinib.
Nakatomi K; Soda H; Kitazaki T; Nakano H; Uchida K; Urabe S; Nakamura Y; Hayashi T; Tsukamoto K; Kohno S
Lung Cancer; 2006 May; 52(2):253-5. PubMed ID: 16554105
[TBL] [Abstract][Full Text] [Related]
4. The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.
Comis RL
Oncologist; 2005 Aug; 10(7):467-70. PubMed ID: 16079313
[No Abstract] [Full Text] [Related]
5. Implications of the Iressa Survival Evaluation in Lung Cancer trial and the future of gefitinib.
Belani CP; Ramalingam S
Clin Lung Cancer; 2005 Jan; 6(4):203-4. PubMed ID: 15694010
[No Abstract] [Full Text] [Related]
6. Gefitinib for refractory advanced non-small-cell lung cancer.
Moriguchi H; Kim TY; Sato C
Lancet; 2006 Jan; 367(9507):299-300. PubMed ID: 16443032
[No Abstract] [Full Text] [Related]
7. [New era in cancer therapy. Gefitinib: small molecule--strong action].
Arnheim K
MMW Fortschr Med; 2004 Nov; 146(47):70-1. PubMed ID: 15624666
[No Abstract] [Full Text] [Related]
8. Increasing osteoblastic lesions as a manifestation of a major response to gefitinib.
Garfield D
J Thorac Oncol; 2006 Oct; 1(8):859-60. PubMed ID: 17409972
[No Abstract] [Full Text] [Related]
9. Final overall survival results from a phase III, randomized, placebo-controlled, parallel-group study of gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804).
Zhao H; Fan Y; Ma S; Song X; Han B; Cheng Y; Huang C; Yang S; Liu X; Liu Y; Lu S; Wang J; Zhang S; Zhou C; Wang M; Zhang L;
J Thorac Oncol; 2015 Apr; 10(4):655-64. PubMed ID: 25546556
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of gefitinib on Chinese patients with locally advanced or metastatic non-small cell lung cancer: a clinical trial].
Guan ZZ; Zhang L; Li LY; Jiang GL; Liu XY; Chu DT; Zhao HY; Li W
Ai Zheng; 2005 Aug; 24(8):980-4. PubMed ID: 16086877
[TBL] [Abstract][Full Text] [Related]
11. Gefitinib in recurrent non-small-cell lung cancer: an IDEAL trial?
Johnson DH; Arteaga CL
J Clin Oncol; 2003 Jun; 21(12):2227-9. PubMed ID: 12748243
[No Abstract] [Full Text] [Related]
12. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study.
Maemondo M; Minegishi Y; Inoue A; Kobayashi K; Harada M; Okinaga S; Morikawa N; Oizumi S; Tanaka T; Isobe H; Kudoh S; Hagiwara K; Nukiwa T; Gemma A
J Thorac Oncol; 2012 Sep; 7(9):1417-22. PubMed ID: 22895139
[TBL] [Abstract][Full Text] [Related]
13. Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
Yang XB; Wu WY; Long SQ; Deng H; Pan ZQ; He WF; Zhou YS; Liao GY; Li QP; Xiao SJ; Cai JZ
Trials; 2015 Apr; 16():146. PubMed ID: 25873045
[TBL] [Abstract][Full Text] [Related]
14. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.
Kim ES; Hirsh V; Mok T; Socinski MA; Gervais R; Wu YL; Li LY; Watkins CL; Sellers MV; Lowe ES; Sun Y; Liao ML; Osterlind K; Reck M; Armour AA; Shepherd FA; Lippman SM; Douillard JY
Lancet; 2008 Nov; 372(9652):1809-18. PubMed ID: 19027483
[TBL] [Abstract][Full Text] [Related]
15. Low-dose gefitinib treatment for patients with advanced non-small cell lung cancer harboring sensitive epidermal growth factor receptor mutations.
Satoh H; Inoue A; Kobayashi K; Maemondo M; Oizumi S; Isobe H; Gemma A; Saijo Y; Yoshizawa H; Hagiwara K; Nukiwa T
J Thorac Oncol; 2011 Aug; 6(8):1413-7. PubMed ID: 21681118
[TBL] [Abstract][Full Text] [Related]
16. Gefitinib plus docetaxel in non-small-cell lung cancer.
Costa DB; Kobayashi S
Lancet; 2009 Feb; 373(9663):541; author reply 542. PubMed ID: 19217979
[No Abstract] [Full Text] [Related]
17. Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study.
Asami K; Koizumi T; Hirai K; Ameshima S; Tsukadaira A; Morozumi N; Morikawa A; Atagi S; Kawahara M
Clin Lung Cancer; 2011 Nov; 12(6):387-92. PubMed ID: 21729650
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of gefitinib in a patient with lung cancer associated with idiopathic pulmonary fibrosis.
Kishi K; Nakata K; Yoshimura K
J Thorac Oncol; 2006 Sep; 1(7):733-4. PubMed ID: 17409949
[No Abstract] [Full Text] [Related]
19. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
Douillard JY; Shepherd FA; Hirsh V; Mok T; Socinski MA; Gervais R; Liao ML; Bischoff H; Reck M; Sellers MV; Watkins CL; Speake G; Armour AA; Kim ES
J Clin Oncol; 2010 Feb; 28(5):744-52. PubMed ID: 20038723
[TBL] [Abstract][Full Text] [Related]
20. Gefitinib plus docetaxel in non-small-cell lung cancer.
Zalcman G; Bergot E
Lancet; 2009 Feb; 373(9663):541; author reply 542. PubMed ID: 19217981
[No Abstract] [Full Text] [Related]
[Next] [New Search]
